Sera Prognostics Inc (SERA) - Total Assets
Based on the latest financial reports, Sera Prognostics Inc (SERA) holds total assets worth $93.54 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sera Prognostics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Sera Prognostics Inc's total assets have evolved over time, based on quarterly financial data. Also see how much is Sera Prognostics Inc worth for the company's overall valuation and market capitalisation.
Sera Prognostics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Sera Prognostics Inc's total assets of $93.54 Million consist of 40.0% current assets and 60.0% non-current assets. Review SERA current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.9% |
| Accounts Receivable | $12.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $910.00K | 0.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Sera Prognostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Sera Prognostics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sera Prognostics Inc's current assets represent 40.0% of total assets in 2025, a decrease from 92.7% in 2019.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, down from 92.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 0.9% of total assets.
Sera Prognostics Inc Competitors by Total Assets
Key competitors of Sera Prognostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Sera Prognostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.12 | 2.02 | 28.27 |
| Quick Ratio | 2.12 | 2.02 | 28.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $26.31 Million | $23.88 Million | $88.14 Million |
Sera Prognostics Inc - Advanced Valuation Insights
This section examines the relationship between Sera Prognostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.76 |
| Asset Growth Rate (YoY) | 40.5% |
| Total Assets | $101.93 Million |
| Market Capitalization | $77.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sera Prognostics Inc's assets below their book value (0.76x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sera Prognostics Inc's assets grew by 40.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sera Prognostics Inc (2019–2025)
The table below shows the annual total assets of Sera Prognostics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $101.93 Million | +40.45% |
| 2024-12-31 | $72.58 Million | -23.96% |
| 2023-12-31 | $95.44 Million | -17.96% |
| 2022-12-31 | $116.33 Million | -20.88% |
| 2021-12-31 | $147.03 Million | +893.71% |
| 2020-12-31 | $14.80 Million | -36.39% |
| 2019-12-31 | $23.26 Million | -- |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of… Read more